Search | Clinical Trials Finder

Conditions: Vitrectomy, Macular Pucker, Retinal Edema
Interventions: Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%; Drug
Lead sponsor: Kovach Eye Institute; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Elmhurst, Illinois

Conditions: Meningioma, Meningioma, Adult
Interventions: Avelumab, Proton Therapy, Surgery; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes, Metastatic Malignant Neoplasm to the Leptomeninges
Interventions: Intra thecal methotrexate, topotecan, cyclophosphamide; Drug
Lead sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Interventions: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide; Biological · Combination Product
Lead sponsor: BioEclipse Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • La Jolla, California • Stanford, California

Conditions: Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Melanoma
Interventions: Community Based Strategies for Early Detection of Melanoma; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Head and Neck Cancer, Neck Dissection, Postoperative Complications
Interventions: Porcine Extracellular Matrix Nerve Wrap (AxoGuard Nerve Protector™); Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: High Grade Glioma
Interventions: nanoliposomal irinotecan; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy, Neurotoxicity Syndromes, Neuropathy
Interventions: Threshold Tracking Nerve Conduction Studies; Diagnostic Test
Lead sponsor: Ka-Wai Ho; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Glioblastoma Multiforme
Interventions: Temozolomide and SCH66336; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma
Interventions: Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection, cisplatin and etoposide; Drug · Radiation · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more

Conditions: Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
Interventions: RO7293583, Tocilizumab, Obinutuzumab, Adalimumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Melanoma, Metastatic Malignant Neoplasm in the Spine, Renal Cell Carcinoma, Soft Tissue Sarcoma, Spinal Cord Compression
Interventions: Image-Guided Adaptive Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Radiation · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Brain and Central Nervous System Tumors
Interventions: porfimer sodium, adjuvant therapy, conventional surgery; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Urinary Incontinence, Urge
Interventions: CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System; Device
Lead sponsor: Uro Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 15
States / cities: Laguna Hills, California • Los Angeles, California • Orange, California + 12 more

Conditions: Brain Tumor, Brain Neoplasms, Brain Cancer, Glioma, Glioblastoma
Interventions: Ultrasound; Diagnostic Test
Lead sponsor: Hospital del Rio Hortega; Other
Eligibility: 15 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma, Ocular Melanoma, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 7
States / cities: Chicago, Illinois • New York, New York • Durham, North Carolina + 3 more

Conditions: Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Oral Complications, Ovarian Cancer, Pain, Sarcoma
Interventions: management of therapy complications, pain therapy; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Glioma, Glioma of Brain, Glioma of Spinal Cord
Interventions: Multilingual Aphasia Examination, Language paradigms + RS fMRI, Language paradigms + RS fMRI + one anatomical sequence; Behavioral · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: New York, New York

Conditions: Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions: Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Echocardiography Test, FDG-Positron Emission Tomography, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Resection; Biological · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Duarte, California

Conditions: Convergence Insufficiency, Binocular Vision Disorder
Interventions: Home-based Pencil Push-Up Therapy, Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics, Office-based Vision Therapy/Orthoptics, Placebo Office-based Vision Therapy/Orthoptics; Behavioral
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 9 Years to 18 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 9
States / cities: Birmingham, Alabama • Fullerton, California • La Jolla, California + 6 more

Conditions: Glioblastoma
Interventions: Lixumistat - Cohort 1, Lixumistat - Cohort 2; Drug
Lead sponsor: Macarena De La Fuente, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Malignant Melanoma, Head and Neck Cancer
Interventions: Filgrastim; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Interventions: MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI; Device · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 3 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors

Community Based Strategies for Early Detection of Melanoma

Porcine Extracellular Matrix Nerve Wrap in Neck Dissection for Head and Neck Cancer

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy

Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme

A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery

High Light and Low Light Dose PDT in Glioma

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

Brain Tumor Intraoperative Ultrasound Database

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Convergence Insufficiency Treatment Trial (CITT)

Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma

Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors